|Bid||0.8611 x 900|
|Ask||0.8800 x 1200|
|Day's Range||0.8618 - 0.9782|
|52 Week Range||0.5900 - 18.5400|
|Beta (5Y Monthly)||0.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 21, 2024 - Feb 26, 2024|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.86|
Subscribe to Yahoo Finance Plus to view Fair Value for ACRS
Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Aclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news.
— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and Webcast Today at 8:00 AM ET — WAYNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced top-line results from a Phase 2b study of zunsemetinib (A